All In Biotech

Drug Trial Radar · NCT07251023

Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia

Multicenter Randomized Double-blind Placebo-controlled Active Comparator-controlled Study to Assess the Efficacy and Safety of DMB-I (Dimebon®, INN: Latrepirdine) in Patients With Dementia Associated With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Nov 20, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Bigespas LTDIndustry
Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults. It will also learn about the safety of DMB-I (INN: Latrepirdine). The main questions it aims to answer are: * Does DMB-I improve cognitive functions in patients with dementia associated with Alzheimer's disease, and how sigificant the improvement is? * What medical problems do participants have when taking DMB-I? Researchers will compare DMB-I to a placebo (a look-alike substance that contains no drug) to see if the study drug works to treat Alzheimer type dementia. * Is DMB-I effective and safe when taken long-term? Participants will: Take the study drug or a placebo (with or without Akatinol Memantine®) every day for 26 weeks at Stage 1 of the study, and take the study drug (with or without Akatinol Memantine®) every day for 26 weeks at Stage 2 of the study. Visit the clinic 13 times for checkups and tests Keep a diary of their symptoms

Conditions

  • Alzheimer Type Dementia

Interventions

  • DMB-I (INN: Latrepirdine)Drug

    Active agent: Dimethylmethylpyridinylethyltetrahydrocarboline. Investigational drug in the study

  • Memantine Hydrochloride 20 MGDrug

    Memantine is used to treat moderate to severe Alzheimer's disease. Active comparator drug in the study

  • PlaceboDrug

    Placebo comparator (dummy) in the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the change in ADAS-Cog Scale overall score at Week 26 compared to baseline (Week 0) in patients receiving DMB-I (Group 1) Vs. patients receiving placebo (Group 2)Time frame: Baseline (Week 0) Vs. Week 26

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • State autonomous healthcare institution "Transregional Clinical Diagnostic Center"

    Kazan', Russia · Recruiting

  • Moscow State budgetary healthcare institution "City Clinical Hospital named after V.M. Buyanov of the Moscow Healthcare Department"

    Moscow, Russia · Recruiting

  • Federal State Budgetary Institution "Federal Center for Brain and Neurotechnology" of the Federal Medical and Biological Agency

    Moscow, Russia · Recruiting

  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

    Moscow, Russia · Recruiting

  • Nizhny Novgorod region State budgetary healthcare institution " Nizhny Novgorod Clinical Psychiatric Hospital No. 1"

    Nizhny Novgorod, Russia · Recruiting

  • State budgetary healthcare institution "Leningrad Regional Mental Health Center"

    Roshchino, Russia · Recruiting

  • "Medical Center Nova Vita" LLC

    Rostov-on-Don, Russia · Recruiting

  • Saint Petersburg State budgetary healthcare institution "Psychiatric Hospital No. 1 named after P.P. Kashchenko"

    Saint Petersburg, Russia · Recruiting

  • "Medical services" LLC

    Saint Petersburg, Russia · Recruiting

  • Saint Petersburg State budgetary healthcare institution "Psychoneurologic dispensary № 5"

    Saint Petersburg, Russia · Recruiting

  • "Sphera Med" LLC

    Saint Petersburg, Russia · Recruiting

  • Saint Petersburg State budgetary healthcare institution "City Hospital No. 40 of Kurortniy district"

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.